Aclarion Inc.
ACON | NASDAQ
$2.63
+$0.17 (+6.91%)
At close: Sep 22, 2026, 3:59 PM ET
$2.63
$0 (0.00%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Company Profile
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Key Executives
| Name | Position |
|---|---|
| Brent Ness | Chief Executive Officer, President & Director |
| Gregory A. Gould | Chief Financial Officer |
| Jeffrey John Thramann | Executive Chairman |
| Ryan Bond | Chief Strategy Officer |
Aclarion Inc.
| Country | United States |
| IPO Date | Apr 21, 2022 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Brent Ness |
Contact Details
8181 Arista Place Broomfield,
California 80021 United States
Stock Details
| Ticker Symbol | ACON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001635077 |
| CUSIP Number | 655187409 |
| ISIN Number | US6551874091 |
| SIC Code |
Add to Watchlist
Select watchlists to add or remove ACON